Phathom Pharmaceuticals Statistics
Share Statistics
Phathom Pharmaceuticals has 69.81M
shares outstanding. The number of shares has increased by 18.97%
in one year.
| Shares Outstanding | 69.81M |
| Shares Change (YoY) | 18.97% |
| Shares Change (QoQ) | 1.84% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 11.18M, so 16.05% of the outstanding
shares have been sold short.
| Short Interest | 11.18M |
| Short % of Shares Out | 16.05% |
| Short % of Float | 26.82% |
| Short Ratio (days to cover) | 3.18 |
Valuation Ratios
The PE ratio is -1.53 and the forward
PE ratio is -12.7.
Phathom Pharmaceuticals's PEG ratio is
-0.04.
| PE Ratio | -1.53 |
| Forward PE | -12.7 |
| PS Ratio | 9.28 |
| Forward PS | 0.4 |
| PB Ratio | -2.02 |
| P/FCF Ratio | -1.92 |
| PEG Ratio | -0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Phathom Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.2,
with a Debt / Equity ratio of -0.8.
| Current Ratio | 4.2 |
| Quick Ratio | 4.16 |
| Debt / Equity | -0.8 |
| Debt / EBITDA | -0.77 |
| Debt / FCF | -0.76 |
| Interest Coverage | -3.85 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $129,395.78 |
| Profits Per Employee | $-782,964.87 |
| Employee Count | 427 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 2.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -57.7% in the
last 52 weeks. The beta is 0.15, so Phathom Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -57.7% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 9.43 |
| Relative Strength Index (RSI) | 55.85 |
| Average Volume (20 Days) | 1,684,204 |
Income Statement
In the last 12 months, Phathom Pharmaceuticals had revenue of 55.25M
and earned -334.33M
in profits. Earnings per share was -5.29.
| Revenue | 55.25M |
| Gross Profit | 47.28M |
| Operating Income | -277.47M |
| Net Income | -334.33M |
| EBITDA | -261.52M |
| EBIT | -262.32M |
| Earnings Per Share (EPS) | -5.29 |
Full Income StatementBalance Sheet
The company has 297.26M in cash and 201.91M in
debt, giving a net cash position of 95.35M.
| Cash & Cash Equivalents | 297.26M |
| Total Debt | 201.91M |
| Net Cash | 95.35M |
| Retained Earnings | -1.26B |
| Total Assets | 294.21M |
| Working Capital | 190.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -266.77M
and capital expenditures 0, giving a free cash flow of -266.9M.
| Operating Cash Flow | -266.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | -266.9M |
| FCF Per Share | -4.22 |
Full Cash Flow StatementMargins
Gross margin is 85.57%, with operating and profit margins of -502.18% and -605.09%.
| Gross Margin | 85.57% |
| Operating Margin | -502.18% |
| Pretax Margin | -605.09% |
| Profit Margin | -605.09% |
| EBITDA Margin | -473.33% |
| EBIT Margin | -502.18% |
| FCF Margin | -483.07% |
